IL158794A0 - The use of adenosine and analogues for producing medicines for the treatment of the insulin resistance syndrome and diabetes - Google Patents
The use of adenosine and analogues for producing medicines for the treatment of the insulin resistance syndrome and diabetesInfo
- Publication number
- IL158794A0 IL158794A0 IL15879402A IL15879402A IL158794A0 IL 158794 A0 IL158794 A0 IL 158794A0 IL 15879402 A IL15879402 A IL 15879402A IL 15879402 A IL15879402 A IL 15879402A IL 158794 A0 IL158794 A0 IL 158794A0
- Authority
- IL
- Israel
- Prior art keywords
- adenosine
- analogues
- diabetes
- treatment
- insulin resistance
- Prior art date
Links
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 title 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 title 1
- 208000031773 Insulin resistance syndrome Diseases 0.000 title 1
- 229960005305 adenosine Drugs 0.000 title 1
- 206010012601 diabetes mellitus Diseases 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01111651A EP1258247A1 (en) | 2001-05-14 | 2001-05-14 | Adenosine analogues for the treatment of insulin resistance syndrome and diabetes |
| PCT/EP2002/005301 WO2002092093A1 (en) | 2001-05-14 | 2002-05-14 | Adenosine analogues for the treatment of the insulin resistance syndrome and diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL158794A0 true IL158794A0 (en) | 2004-05-12 |
Family
ID=8177414
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL15879402A IL158794A0 (en) | 2001-05-14 | 2002-05-14 | The use of adenosine and analogues for producing medicines for the treatment of the insulin resistance syndrome and diabetes |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20030176390A1 (cs) |
| EP (2) | EP1258247A1 (cs) |
| JP (1) | JP2004533448A (cs) |
| KR (1) | KR20040002962A (cs) |
| CN (1) | CN1518450A (cs) |
| BG (1) | BG108356A (cs) |
| BR (1) | BR0209650A (cs) |
| CA (1) | CA2447408A1 (cs) |
| CO (1) | CO5540288A2 (cs) |
| CZ (1) | CZ20033079A3 (cs) |
| EA (1) | EA007253B1 (cs) |
| EE (1) | EE200300551A (cs) |
| HR (1) | HRP20030928A2 (cs) |
| HU (1) | HUP0400464A3 (cs) |
| IL (1) | IL158794A0 (cs) |
| MX (1) | MXPA03010336A (cs) |
| NO (1) | NO20035056D0 (cs) |
| NZ (1) | NZ529390A (cs) |
| PL (1) | PL364573A1 (cs) |
| SK (1) | SK14052003A3 (cs) |
| WO (1) | WO2002092093A1 (cs) |
| YU (1) | YU90203A (cs) |
| ZA (1) | ZA200308777B (cs) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GT200500281A (es) * | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
| GB0500785D0 (en) * | 2005-01-14 | 2005-02-23 | Novartis Ag | Organic compounds |
| GB0607944D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| GB0607950D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| GB0607953D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| GB0607948D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| CA2649215A1 (en) * | 2006-04-21 | 2007-11-01 | Novartis Ag | 2,6,9-trisubstituted purine compounds as adenosine aza receptor modulators |
| EP1889846A1 (en) | 2006-07-13 | 2008-02-20 | Novartis AG | Purine derivatives as A2a agonists |
| EP1903044A1 (en) * | 2006-09-14 | 2008-03-26 | Novartis AG | Adenosine Derivatives as A2A Receptor Agonists |
| BRPI0718792A2 (pt) * | 2006-11-10 | 2013-12-03 | Novartis Ag | Compostos orgânicos |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| WO2009131196A1 (ja) * | 2008-04-24 | 2009-10-29 | 武田薬品工業株式会社 | 置換ピロリジン誘導体およびその用途 |
| US8933024B2 (en) | 2010-06-18 | 2015-01-13 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| CN119798352A (zh) * | 2024-01-15 | 2025-04-11 | 中国医学科学院药物研究所 | 化合物yzg-331的晶型及其制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8729994D0 (en) * | 1987-12-23 | 1988-02-03 | Glaxo Group Ltd | Chemical compounds |
| US5055569A (en) * | 1989-10-19 | 1991-10-08 | G. D. Searle & Co. | N-(6)-substituted adenosine compounds |
| HUT61567A (en) * | 1990-12-07 | 1993-01-28 | Sandoz Ag | Process for producing new pharmaceutical compositions comprising 2'-o-alkyladenosine derivatives and for producing 6-cyclohexyl-2'-o-methyladenosinehydrate |
| UA51716C2 (uk) * | 1996-07-08 | 2002-12-16 | Авентіс Фармасьютікалз Продактс Інк. | Сполуки, що мають гіпотензивну, кардіопротекторну, анти-ішемічну та антиліполітичну властивості, фармацевтична композиція та способи лікування |
| US6376472B1 (en) * | 1996-07-08 | 2002-04-23 | Aventis Pharmaceuticals, Inc. | Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties |
| GB9723590D0 (en) * | 1997-11-08 | 1998-01-07 | Glaxo Group Ltd | Chemical compounds |
| US6258793B1 (en) * | 1999-12-03 | 2001-07-10 | Cv Therapeutics, Inc. | N6 heterocyclic 5′ modified adenosine derivatives |
-
2001
- 2001-05-14 EP EP01111651A patent/EP1258247A1/en not_active Withdrawn
-
2002
- 2002-05-14 EE EEP200300551A patent/EE200300551A/xx unknown
- 2002-05-14 WO PCT/EP2002/005301 patent/WO2002092093A1/en not_active Application Discontinuation
- 2002-05-14 PL PL02364573A patent/PL364573A1/xx not_active Application Discontinuation
- 2002-05-14 SK SK1405-2003A patent/SK14052003A3/sk unknown
- 2002-05-14 US US10/145,207 patent/US20030176390A1/en not_active Abandoned
- 2002-05-14 CN CNA028112393A patent/CN1518450A/zh active Pending
- 2002-05-14 IL IL15879402A patent/IL158794A0/xx unknown
- 2002-05-14 YU YU90203A patent/YU90203A/sh unknown
- 2002-05-14 HR HR20030928A patent/HRP20030928A2/xx not_active Application Discontinuation
- 2002-05-14 CZ CZ20033079A patent/CZ20033079A3/cs unknown
- 2002-05-14 CA CA002447408A patent/CA2447408A1/en not_active Abandoned
- 2002-05-14 NZ NZ529390A patent/NZ529390A/en unknown
- 2002-05-14 EA EA200301231A patent/EA007253B1/ru not_active IP Right Cessation
- 2002-05-14 MX MXPA03010336A patent/MXPA03010336A/es not_active Application Discontinuation
- 2002-05-14 BR BR0209650-1A patent/BR0209650A/pt not_active IP Right Cessation
- 2002-05-14 EP EP02769485A patent/EP1404338A1/en not_active Withdrawn
- 2002-05-14 JP JP2002589010A patent/JP2004533448A/ja not_active Abandoned
- 2002-05-14 KR KR10-2003-7014888A patent/KR20040002962A/ko not_active Withdrawn
- 2002-05-14 HU HU0400464A patent/HUP0400464A3/hu unknown
-
2003
- 2003-11-11 ZA ZA200308777A patent/ZA200308777B/en unknown
- 2003-11-12 CO CO03100204A patent/CO5540288A2/es not_active Application Discontinuation
- 2003-11-13 BG BG108356A patent/BG108356A/bg unknown
- 2003-11-13 NO NO20035056A patent/NO20035056D0/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR0209650A (pt) | 2004-07-13 |
| EE200300551A (et) | 2004-02-16 |
| NZ529390A (en) | 2006-06-30 |
| KR20040002962A (ko) | 2004-01-07 |
| CN1518450A (zh) | 2004-08-04 |
| EP1258247A1 (en) | 2002-11-20 |
| EP1404338A1 (en) | 2004-04-07 |
| HUP0400464A2 (hu) | 2004-07-28 |
| HUP0400464A3 (en) | 2007-03-28 |
| JP2004533448A (ja) | 2004-11-04 |
| BG108356A (bg) | 2004-12-30 |
| NO20035056D0 (no) | 2003-11-13 |
| EA200301231A1 (ru) | 2004-04-29 |
| CO5540288A2 (es) | 2005-07-29 |
| HRP20030928A2 (en) | 2005-10-31 |
| CA2447408A1 (en) | 2002-11-21 |
| MXPA03010336A (es) | 2004-03-16 |
| WO2002092093A1 (en) | 2002-11-21 |
| CZ20033079A3 (cs) | 2004-08-18 |
| ZA200308777B (en) | 2006-04-26 |
| EA007253B1 (ru) | 2006-08-25 |
| SK14052003A3 (sk) | 2004-07-07 |
| YU90203A (sh) | 2006-08-17 |
| US20030176390A1 (en) | 2003-09-18 |
| PL364573A1 (en) | 2004-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL161155A0 (en) | Treatment of insulin resistance syndrome and type 2 diabetes with pde9 inhibitors | |
| IL158794A0 (en) | The use of adenosine and analogues for producing medicines for the treatment of the insulin resistance syndrome and diabetes | |
| HRP20030949A2 (en) | Pulmonary administration of chemically modified insulin | |
| MXPA03004936A (es) | Compuestos ciclicos fusionados y uso medicinal de los mismos. | |
| HUS1100028I1 (hu) | 8-[3-amino-piperidin-1-il]-xantinok, a vegyületek elõállítása és gyógyszerként való alkalmazása | |
| ZA200402688B (en) | Method and composition for preventing or reducing the symptons of insulin resistance syndrome. | |
| AU2003243551A1 (en) | Use of an anti-endotoxin drug in the prevention and treatment of disease | |
| AU2003220317A8 (en) | Methods and drug delivery systems for the treatment of orofacial diseases | |
| PL1623228T3 (pl) | APOCIII i leczenie oraz diagnozowanie cukrzycy | |
| AU2003252182A8 (en) | Therapeutic treatment for the metabolic syndrome and type 2 diabetes | |
| AU2003255612A8 (en) | Novel multimeric molecules, the preparation method thereof and use of same for the preparation of medicaments | |
| PL369148A1 (en) | Product comprising mikanolide, dihydromikanolide or an analogue thereof combined with another anti-cancer agent for therapeutic use in cancer treatment | |
| EP1476174A4 (en) | PHARMACEUTICAL PREPARATION WITH PROPHYLACTIC EFFECTS ON LAMIVUDINE-RELATED REACTIONS AND PHARMACORESISTANCE, AND METHODS OF USING THE SAME | |
| AU2003238242A1 (en) | Use of an anti-endotoxin drug in the prevention and treatment of disease | |
| AU2003272260A8 (en) | Verifiable absorption drug delivery form based on cyclodextrins | |
| HUP0303597A3 (en) | Diposable vaginal cannula for the simultaneous administration of drugs in different forms | |
| IL173918A0 (en) | Substituted thienoimidazoles, method for production and use thereof as medicament or diagnostic and medicaments comprising the same | |
| AU2003294952A8 (en) | 3,3-dimethyl-8-oxoisoquinolines for medical purposes, methods for the production thereof, medicaments containing said compounds and the use of the same | |
| GB0212790D0 (en) | Medicament for the treatment of diabetes | |
| IL164951A0 (en) | The treatment of pain with lfendropil | |
| GB0117134D0 (en) | Treatment of the insulin resistance syndrome | |
| GB0030649D0 (en) | Treatment of the insulin resistance syndrome | |
| ZA200301030B (en) | Treatment of the insulin resistance syndrome. | |
| SI1465641T1 (sl) | Zdravila, ki vsebujejo devterij, za zdravljenje sladkorne bolezni | |
| AU2002249329A1 (en) | Method for determining the therapeutic efficacy of a medicament against parkinson's disease and/or parkinson syndrome using anfri/fri mouse as a model |